SEC Comment Letter for Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Jun 10, 2026
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: June 10, 2026 · CIK: 0001228627 · Accession: 0000000000-26-005851
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296551
Letter
June 10, 2026 George Magrath Chief Executive Officer Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, NC 27713 Re: Opus Genetics, Inc. Registration Statement on Form S-3 Filed June 5, 2026 File No. 333-296551 Dear George Magrath: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nick DeAngelis, Esq.
Show Raw Text
June 10, 2026 George Magrath Chief Executive Officer Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham, NC 27713 Re: Opus Genetics, Inc. Registration Statement on Form S-3 Filed June 5, 2026 File No. 333-296551 Dear George Magrath: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nick DeAngelis, Esq.